These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 19948506

  • 1. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
    Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E, Atrial Arrhythmia Conversion Trial Investigators.
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):652-9. PubMed ID: 19948506
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN, Mangal B.
    BMC Cardiovasc Disord; 2016 May 28; 16():113. PubMed ID: 27233239
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Drenning DH, Atrial Arrhythmia Conversion Trial (ACT-III) Investigators.
    Am J Cardiol; 2010 Nov 01; 106(9):1277-83. PubMed ID: 21029824
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial.
    Camm AJ, Toft E, Torp-Pedersen C, Vijayaraman P, Juul-Moller S, Ip J, Beatch GN, Dickinson G, Wyse DG, Scene 2 Investigators.
    Europace; 2012 Jun 01; 14(6):804-9. PubMed ID: 22291438
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
    Mao Z, Wheeler JJ, Townsend R, Gao Y, Kshirsagar S, Keirns JJ.
    J Pharmacokinet Pharmacodyn; 2011 Oct 01; 38(5):541-62. PubMed ID: 21786177
    [Abstract] [Full Text] [Related]

  • 6. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
    Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ, Atrial Arrhythmia Conversion Trial Investigators.
    Circulation; 2008 Mar 25; 117(12):1518-25. PubMed ID: 18332267
    [Abstract] [Full Text] [Related]

  • 7. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
    Torp-Pedersen C, Camm AJ, Butterfield NN, Dickinson G, Beatch GN.
    Int J Cardiol; 2013 Jun 05; 166(1):147-51. PubMed ID: 22108512
    [Abstract] [Full Text] [Related]

  • 8. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG, Roos JS, Kavanagh KM, Dickinson G.
    Am Heart J; 2010 Jun 05; 159(6):1095-101. PubMed ID: 20569725
    [Abstract] [Full Text] [Related]

  • 9. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
    Stiell IG, Dickinson G, Butterfield NN, Clement CM, Perry JJ, Vaillancourt C, Calder LA.
    Acad Emerg Med; 2010 Nov 05; 17(11):1175-82. PubMed ID: 21175515
    [Abstract] [Full Text] [Related]

  • 10. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN.
    Circ Arrhythm Electrophysiol; 2011 Oct 05; 4(5):637-43. PubMed ID: 21841207
    [Abstract] [Full Text] [Related]

  • 11. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
    Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch G, AVRO Investigators.
    J Am Coll Cardiol; 2011 Jan 18; 57(3):313-21. PubMed ID: 21232669
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y, Dobrev D.
    Vasc Health Risk Manag; 2013 Jan 18; 9():165-75. PubMed ID: 23637539
    [Abstract] [Full Text] [Related]

  • 13. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
    Duggan ST, Scott LJ.
    Drugs; 2011 Jan 22; 71(2):237-52. PubMed ID: 21275448
    [Abstract] [Full Text] [Related]

  • 14. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR.
    Piccini JP, Pritchett EL, Davison BA, Cotter G, Wiener LE, Koch G, Feld G, Waldo A, van Gelder IC, Camm AJ, Kowey PR, Iwashita J, Dittrich HC.
    Heart Rhythm; 2016 Sep 22; 13(9):1777-83. PubMed ID: 27108936
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
    Beatch GN, Bhirangi K, Juul-Moller S, Rustige J.
    J Cardiovasc Pharmacol; 2017 Feb 22; 69(2):86-92. PubMed ID: 27828791
    [Abstract] [Full Text] [Related]

  • 16. Vernakalant: RSD 1235, RSD-1235, RSD1235.
    Drugs R D; 2007 Feb 22; 8(4):259-65. PubMed ID: 17596113
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
    Savelieva I, Graydon R, Camm AJ.
    Europace; 2014 Feb 22; 16(2):162-73. PubMed ID: 24108230
    [Abstract] [Full Text] [Related]

  • 18. Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
    Lévy S, Hartikainen J, Ritz B, Juhlin T, Carbajosa-Dalmau J, Domanovits H.
    Cardiovasc Drugs Ther; 2021 Apr 22; 35(2):283-292. PubMed ID: 33206300
    [Abstract] [Full Text] [Related]

  • 19. Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation.
    Ma W, Guo X, Wang Q, Sun G, Wang J.
    J Cardiovasc Pharmacol; 2020 Jul 22; 76(1):32-41. PubMed ID: 32251022
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
    Nørgaard BL, Wachtell K, Christensen PD, Madsen B, Johansen JB, Christiansen EH, Graff O, Simonsen EH.
    Am Heart J; 1999 Jun 22; 137(6):1062-9. PubMed ID: 10347332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.